Millipore Corp

Millipore — Q4 2004 Earnings Presentation

30 slides from Millipore's earnings presentation, Feb 1, 2005

  1. Slide 1: Millipore Conference Call, Fourth Quarter and Year-End Results

    Millipore Conference Call, January 27, 2005 Fourth Quarter and Year-End Results

  2. Slide 2: Forward-looking statements/risk factors

    Forward-looking statements/risk factors In order to take advantage of the safe harbor provisions of the private securities litigation reform act of 1995, you should understand that we will be making forward-looking statements in this conference. These statements involve a number of risks and uncerta

  3. Slide 3: Regulation G: Use of non-GAAP financial measures

    Regulation G: Use of non-GAAP financial measures In addition to analyzing U.S. GAAP financial results, management also analyzes “non-GAAP” and “pro forma” financial measures as we believe these measures may allow for a better understanding of the underlying business trends. “Constant currency” is a

  4. Slide 4: New CEO started January 1, 2005

    New CEO started January 1, 2005 Martin Madaus Formerly head of Roche Diagnostics in US Focus: top line growth and innovation First priorities Immersion in business & getting to know employees Getting to know investors Drive 2005 performance

  5. Slide 5: Q4 2004 summary

    Q4 2004 summary 4% revenue growth over Q4 2003 1% revenue growth in constant currency GAAP earnings per share was $0.49 Pro forma earnings per share was $0.49 Biotechnology: 3% growth in constant currency Life science: 2% decline in constant currency Other bioscience: flat in constant currency

  6. Slide 6: FY 2004 summary

    FY 2004 summary 10% revenue growth over 2003 6% revenue growth in constant currency GAAP earnings per share was $2.10 Pro forma earnings per share was $2.14 Biotechnology: 9% growth in constant currency Life science: 6% growth in constant currency Other bioscience: 3% growth in constant currency

  7. Slide 7: FY 2004 revenues (in constant currencies)

    FY 2004 revenues (in constant currencies) Asia/Pacific 19% Europe 36% Americas 45% FY 2004 Equipment 18% Consumables and services 82% FY 2004 Other bioscience applications 51% Biotechnology 35% Life science 14% FY 2004

  8. Slide 8: Q4 revenue growth - by market

    Q4 revenue growth - by market $ in millions Q4 2004 Q4 2003 Q4 % Growth Biotechnology $ 71 $ 69 3% Life science 28 29 (2%) Other bioscience 103 102 —% Total constant currency 202 200 1% Foreign exchange 23 16 Total U.S. dollar $225 $216 4%

  9. Slide 9: 2004 revenue growth - by market

    2004 revenue growth—by market $ in millions 2004 2003 % Growth Biotechnology $286 $262 9% Life science 115 108 6% Other bioscience 408 395 3% Total constant currency 809 765 6% Foreign exchange 74 35 Total U.S. dollar $883 $800 10%

  10. Slide 10: Biotechnology - quarterly revenue growth and trends

    Biotechnology – quarterly revenue growth and trends (in constant currencies) Quarterly Growth Q1 2003 – Q4 2004 Revenues by Quarter Q1 2003 – Q4 2004—$ Millions 30% 27% 24% 21% 18% 15% 12% 9% 6% 3% 0% -3% $80 $70 $60 $50 $40 $30 $20 $10 $0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 ‘03 ‘04

  11. Slide 11: Therapeutic antibody pipeline is robust

    Therapeutic antibody pipeline is robust Dec ‘03 Oct ‘04 Jan ‘05 Preclinical 323 365 385 Phase 1 45 48 49 Phase 2 77 77 74 Phase 3 19 18 22 Awaiting Approval 3 1 2 Approved 19 22 23 Total 486 531 555 4 new MAb approvals in the past 12 months More preclinicals, more Phase 3 Millipore involved in some

  12. Slide 12: Life science - quarterly revenue growth and trends

    Life science – quarterly revenue growth and trends (in constant currencies) Quarterly Growth Q1 2003 – Q4 2004 Revenues by Quarter Q1 2003 – Q4 2004—$ Millions 30% 25% 20% 15% 10% 5% 0% -5% $35 $30 $25 $20 $15 $10 $5 $0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 ‘03 ‘04

  13. Slide 13: Other bioscience - quarterly revenue growth and trends

    Other bioscience – quarterly revenue growth and trends (in constant currencies) Quarterly Growth Q1 2003 – Q4 2004 Revenues by Quarter Q1 2003 – Q4 2004—$ Millions 25% 20% 15% 10% 5% 0% -5% $120 $100 $80 $60 $40 $20 $0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 ‘03 ‘04

  14. Slide 14: Revenue growth - by geographic region

    Revenue growth—by geographic region Q4 2004 $ in millions Q4 2004 Q4 2003 % Growth % Growth Constant Currency Americas $ 91 $ 89 3% 2% Europe 92 86 7% (1%) Asia/Pacific 42 41 3% —% Total U.S. dollar $225 $216 4% 1% FY 2004 $ in millions 2004 2003 % Growth % Growth Constant Currency Americas $367 $33

  15. Slide 15: Q4 GAAP results

    Q4 GAAP results Actual dollars (In millions, except per share data) Q4 2004 Q4 2003 % Growth Sales $ 225.4 $ 215.8 4% Gross profit 114.8 109.0 5% % of sales 50.9% 50.5% SG&A 72.0 64.9 11% % of sales 32.0% 30.1% R&D 15.3 16.5 (7%) % of sales 6.8% 7.6% Operating income 27.5 27.6 —% % of sales 12.2% 12

  16. Slide 16: Q4 pro forma results

    Q4 pro forma results* Actual Dollars (In millions, except per share data) Q4 2004 Q4 2003 % Growth Sales $ 225.4 $ 215.8 4% Gross profit* 114.8 111.4 3% % of sales 50.9% 51.6% SG&A* 67.7 60.5 12% % of sales 30.0% 28.0% R&D* 15.3 15.0 2% % of sales 6.8% 7.0% Operating income* 31.8 35.9 (11%) % of sal

  17. Slide 17: FY GAAP results

    FY GAAP results Year ended December 31, Actual dollars (In millions, except per share data) 2004 2003 % Growth Sales $ 883.3 $ 799.6 10% Gross profit 471.1 430.4 9% % of sales 53.3% 53.8% SG&A 270.8 246.8 10% % of sales 30.7% 30.9% R&D 62.4 58.4 7% % of sales 7.1% 7.3% Restructuring and other — (1.4

  18. Slide 18: FY pro forma results

    FY pro forma results* Year ended December 31, Actual Dollars (In millions, except per share data) 2004 2003 % Growth Sales $ 883.3 $ 799.6 10% Gross profit* 471.1 432.8 9% % of sales 53.3% 54.1% SG&A* 263.4 242.4 9% % of sales 29.8% 30.3% R&D* 62.4 56.9 10% % of sales 7.1% 7.1% Operating income* 145

  19. Slide 19: 2004 new products: biopharmaceutical process monitoring and manufacturing

    2004 new products: biopharmaceutical process monitoring and manufacturing Steritest™ Equinox Pump Express® Sterilizing-grade High Capacity (SHC) Filters Steritest™ EZ Devices Milliflex® Rapid Microbiology Detection System and Autospray Station Disposable Assemblies Series 3000 Single-round Housings

  20. Slide 20: 2004 new products: life science research and general lab

    2004 new products: life science research and general lab Centrigon® Plus-70 Centrifugal Filter Device MultiScreen®HTS Filter Plate Stericap® PLUS Bottle-top Filter Unit MultiScreen® Deep Well Solvinert Filter Plate 33mm Millex® Syringe Filters with Durapore® Membrane Steripak™ - GP20 Filter Device

  21. Slide 21: Currency effects - Q4 2004

    Currency effects – Q4 2004 Yen/Dollar 10/2/04—12/31/04 115 110 105 100 10/4/2004 10/10/2004 10/16/2004 10/22/2004 10/28/2004 11/3/2004 11/9/2004 11/15/2004 11/21/2004 11/27/2004 12/3/2004 12/9/2004 12/15/2004 12/21/2004 12/27/2004 Euro/Dollar 10/2/04—12/31/04 0.85 0.8 0.75 0.7 10/4/2004 10/10/2004 1

  22. Slide 22: Meeting biotech demand for UF membrane for the next decade

    Meeting biotech demand for UF membrane for the next decade Built new state-of-the-art UF membrane plant in Jaffrey, N.H. UF critical for increasing volume and number of MAb and vaccine therapies Designed to the highest biotech industry standards

  23. Slide 23: Accelerating the flow of new products and technology

    Accelerating the flow of new products and technology Investing $50M in new R&D facility Innovation key to long term growth Focus biotech, core technologies Top-notch labs critical to attracting best scientists

  24. Slide 24: Financial Guidance

    Financial Guidance Revenue growth: Actual dollar: 7 to 9% Constant currency: 5 to 7% Revenue growth by market -constant currency Biotechnology: 7 to 9% Life science: 8 to 10% Other bioscience: 3 to 4% Gross margins: averaging 53.5% of revenue SG&A: 29.5% of revenue R&D: between 7 and 7.5% of revenue

  25. Slide 25: Appendix

    Appendix MILLIPORE

  26. Slide 26: Q4 2004 - GAAP to pro forma reconciliation

    Q4 2004—GAAP to pro forma reconciliation Quarter ended December 31, 2004 Actual dollars (In millions, except per share data) GAAP results Impact of tax normalization Impact of Q4 CEO transition costs and intangible asset write-offs Pro forma results Sales $ 225.4 $ - $ - $ 225.4 Gross profit 114.8 1

  27. Slide 27: Q4 2003 - GAAP to pro forma reconciliation

    Q4 2003—GAAP to pro forma reconciliation Quarter ended December 31, 2003 Actual dollars (In millions, except per share data) GAAP results Impact of tax adjustment Impact of Q4 severance costs and fixed asset write-offs Pro forma results Sales $ 215.8 $ - $ - $ 215.8 Gross profit 109.0 2.4 111.4 % of

  28. Slide 28: FY 2004 - GAAP to pro forma reconciliation

    FY 2004—GAAP to pro forma reconciliation Year ended December 31, 2004 Actual dollars (In millions, except per share data) GAAP results Impact of tax normalization Impact of Q4 CEO transition costs and intangible asset write-offs Pro forma results Net sales $ 883.3 $ - $ - $ 883.3 Gross profit 471.1

  29. Slide 29: FY 2003 - GAAP to pro forma reconciliation

    FY 2003—GAAP to pro forma reconciliation Year ended December 31, 2003 Actual dollars (In millions, except per share data) GAAP results Impact of tax adjustment Impact of Q2 & Q3 restructuring and other and Q4 severance costs and fixed asset write-offs Pro forma results Net sales $ 799.6 $ - $ - $ 79

  30. Slide 30: Millipore

    MILLIPORE

Millipore — Q4 2004 Earnings Presentation on 6ix